Latest news with #VVC
Business Wire
02-07-2025
- Business
- Business Wire
Access Advance Welcomes Global Technology Leaders as Licensees and Licensors to New Video Distribution Patent Pool
BOSTON--(BUSINESS WIRE)--Access Advance LLC ("Advance") today announced the inaugural roster of licensees and licensors for its Video Distribution Patent ("VDP") Pool, marking a significant milestone in the program's rapid market adoption since its January announcement. The participation of major global companies heavily involved in video codec technology demonstrates strong industry support for the comprehensive licensing solution covering HEVC, VVC, VP9, and AV1 codecs. The licensees' participation provides immediate access to the wide-ranging patent portfolio while benefiting from the fixed tiered pricing structure designed to scale with business size. The VDP Pool has successfully attracted a group of licensees/licensors including ByteDance, Kuaishou, NTT Docomo, and Tencent. This represents the beginning of what Access Advance expects to be widespread adoption among content streaming providers seeking simplified codec licensing. The licensees' participation provides immediate access to the wide-ranging patent portfolio while benefiting from the fixed tiered pricing structure designed to scale with business size. "We're pleased to welcome ByteDance, Kuaishou, NTT Docomo and Tencent as our first VDP Pool licensees/licensors. Their commitment to the VDP program demonstrates the practical value of our one-stop-shop approach and the fact that the VDP program has successfully struck a balance between patent owners and implementers," said Peter Moller, CEO of Access Advance. "This milestone shows that the VDP Pool is delivering on its promise to provide simplicity and predictability for online video distributors, allowing them to focus on innovation and content delivery rather than complex patent negotiations." The VDP Pool has also confirmed a large group of licensors representing a strong and substantial portfolio of standard essential patents for video codecs, positioning the pool to provide extensive intellectual property coverage for video streaming services. This initial group of patent owners includes the following internationally recognized technology leaders whose innovations are fundamental to modern video streaming infrastructure: BlackBerry Limited ByteDance Dolby International AB Dolby Laboratories, Inc. Electronics and Telecommunications Research Institute Ewha University-Industry Collaboration Foundation Hangzhou Boyun Technology Co., Ltd. HFI Innovation Inc. Hyundai Motor Company IBEX PT Holdings IDEAHUB Inc. Intellectual Discovery Co., Ltd. JVCKENWOOD Corporation Kia Corporation Koninklijke Philips N.V. KT Corporation Kuaishou Technology Kwangwoon University, Industry-Academic Collaboration Foundation LX Semicon Co., Ltd Mitsubishi Electric Corporation NEC Corporation NTT DOCOMO, Inc. OP Solutions, LLC SK Telecom Co., Ltd. Tencent America LLC University-Industry Cooperation Foundation of Korea Aerospace University University-Industry Cooperation Group of Kyung Hee University V-Nova Limited XRIS Corporation Additional Licensor to be disclosed shortly Additional Licensor to be disclosed shortly "The strong participation from major industry players and patent holders validates our approach and demonstrates that the VDP program is the preferred solution to the market's need for a unified licensing solution that balances the interest of patent owners and implementers," Moller added. "These licensors bring not only essential patent portfolios but also the credibility and scale necessary to make the VDP Pool the preferred licensing destination for streaming video providers globally." The announcement comes as the industry increasingly seeks to license video codec patents directly to content streaming providers, who have benefited significantly from the use of patented, efficient video codecs. Access Advance's approach aims to provide broad access to patented technology while promoting continued innovation in video codec technologies. Access Advance is in the process of finalizing agreements with several more licensors and licensees. More announcements will be made in the coming days and weeks. In addition, the VDP Pool rate structure has been posted to the Access Advance website ( The company encourages all internet video distributors and patent owners to learn more about the program, including available incentives and discounts, by contacting us at licensing@ About Access Advance: Access Advance LLC is an independent licensing administrator company formed to lead the development, administration, and management of patent pools for licensing essential patents of the most important video codec technologies. Access Advance provides a transparent and efficient licensing mechanism for both patent owners and patent implementers. Access Advance manages and administers the HEVC Advance Patent Pool for licensing over 25,500 patents essential to H.265/HEVC technology and the VVC Advance Patent Pool for licensing essential patents to VVC/H.266 technology. The company's Multi-Codec Bridging Agreement provides eligible licensees with a single discounted royalty rate structure for licensees participating in both the HEVC Advance and VVC Advance pools. In addition, Access Advance offers the VDP Pool, a comprehensive licensing solution for video streaming services covering HEVC, VVC, VP9, and AV1 codecs. For more information, please visit:
Business Wire
02-07-2025
- Business
- Business Wire
Access Advance 欢迎全球技术领导者加入成为新视频分发专利池的许可方和被许可方
波士顿--(BUSINESS WIRE)--(美国商业资讯)-- Access Advance LLC （'Advance'） 今天宣布其视频分发专利 （'VDP'） 池的首批许可方和被许可方的名单，这是该专利池自今年 1 月宣布推出以来迅速获得市场认可的一个重要里程碑。这些在视频编解码技术领域占有重要地位的大型跨国公司的参与，表明了业界对涵盖 HEVC、VVC、VP9 和 AV1 编解码器的全面许可解决方案的强力支持。 VDP 专利池已成功吸引了包括NTT Docomo、快手科技、腾讯和字节跳动在内的许可方/被许可方。通过为流媒体服务商提供他们所寻求的更简单的编解码技术许可方案，Access Advance期望其VDP专利池将得到广泛采纳，这些许可方和被许可方的加入，标志着这一历程已经开始。被许可方参与VDP专利池，能够即时获得一个覆盖广泛的专利组合的许可，同时受益于根据业务规模调整的固定分级定价结构。 '我们很高兴地欢迎NTT Docomo、快手科技、腾讯和字节跳动成为我们的许可方/被许可方。他们加入 VDP专利池是对我们一站式许可的实际价值的见证，同时也证明了VDP专利池成功地在专利权人和实施人之间取得平衡'Access Advance 首席执行官 Peter Moller 说。'这一里程碑表明，VDP专利池正在履行其承诺，为流媒体服务商提供简便和可预测的许可方案，使他们能够专注于创新和内容交付，而不是复杂的专利谈判。 VDP 专利池还宣布了首批许可方，这些许可方代表着强大且丰富的视频编解码器标准必要专利组合，使得VDP专利池能够为流媒体服务商提供广泛的知识产权覆盖。首批许可方包括以下国际知名的技术领袖，他们的创新对现代视频流媒体的基础设施至关重要： BlackBerry Limited ByteDance Dolby International AB Dolby Laboratories, Inc. Electronics and Telecommunications Research Institute Ewha University-Industry Collaboration Foundation Hangzhou Boyun Technology Co., Ltd. HFI Innovation Inc. Hyundai Motor Company IBEX PT Holdings IDEAHUB Inc. Intellectual Discovery Co., Ltd. JVCKENWOOD Corporation Kia Corporation Koninklijke Philips N.V. KT Corporation Kuaishou Technology Kwangwoon University, Industry-Academic Collaboration Foundation LX Semicon Co., Ltd Mitsubishi Electric Corporation NEC Corporation NTT Docomo, Inc. OP Solutions, LLC SK Telecom Co., Ltd. Tencent America LLC University-Industry Cooperation Foundation of Korea Aerospace University University-Industry Cooperation Group of Kyung Hee University V-Nova Limited XRIS Corporation Additional licensor to be disclosed shortly Additional licensor to be disclosed shortly '这些在业内占有重要地位的公司和专利权人的积极参与是对我们的理念的认可，也表明VDP专利池为市场提供了一个优选方案，满足了市场对平衡专利权人和实施人利益的统一许可解决方案的需求，'Moller补充说。'这些许可方不仅带来了必要的专利组合，还带来了必要的可信度和规模，使VDP池成为全球流媒体服务商的优选许可方案。 Access Advance宣布首批许可方和被许可方，适逢业界在日益寻求向流媒体服务商直接许可视频编解码专利，而这些服务商已从使用被专利覆盖的高效视频编解码器中获益匪浅。Access Advance 的方案旨在更大范围地普及专利技术的使用，同时促进视频编解码技术的持续创新。 Access Advance 正在与更多许可方和被许可方商讨最终协议。未来几天和几周将发布更多公告。此外，VDP 专利池的费率结构已发布到 Access Advance VDP 网站（ licensing@ 联系我们，了解有关该计划的更多信息，包括可用的激励和折扣。 关于 Access Advance： Access Advance LLC 是一家独立的许可管理公司，旨在领导专利池的开发和管理，以许可最重要的基于标准的视频编解码器技术的基本专利。Access Advance 为专利所有者和专利实施者提供了透明、高效的许可机制。 Access Advance 管理 HEVC Advance 专利池，用于许可 H.265/HEVC 技术必需的 25500 多项专利，以及 VVC Advance 专利池，用于许可 VVC/H.266 技术必需的专利。公司的多编解码器桥接协议为参与 HEVC Advance 和 VVC Advance 池的被许可方提供单一版税费率结构。此外，Access Advance 还提供 VDP 池，这是一个全面的视频流服务许可解决方案，涵盖 HEVC、VVC、VP9 和 AV1 编解码器。如需了解更多信息，请访问： 。
Yahoo
30-05-2025
- Business
- Yahoo
SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold
SCYNEXIS, Inc. (NASDAQ:SCYX) has officially restarted patient dosing in its Phase III MARIO trial for Brexafemme (ibrexafungerp) after the FDA lifted a nearly two-year clinical hold. The hold, initiated over concerns of beta-lactam contamination at the original manufacturing facility, was removed once new drug batches were produced at a separate location. With trial sites now reactivated, patient enrollment has resumed, reaching about 25% of its 220-participant goal. A pharmacist technician sorting pills in a drug pharmacy. The MARIO trial explores Brexafemme's use as an oral follow-up treatment to IV echinocandins for invasive candidiasis, a life-threatening fungal infection. SCYNEXIS, Inc. (NASDAQ:SCYX) received a $10 million milestone payment from GSK after the first new patient was dosed, though disagreements over further payments and trial duties have sparked tension between the two partners. Previously recalled in 2023 due to contamination risks, Brexafemme had FDA approval for treating VVC. While its commercial progress has faced setbacks, projected global revenue could reach $139 million by 2031 if development succeeds. While we acknowledge the potential of SCYX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SCYX and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold
SCYNEXIS, Inc. (NASDAQ:SCYX) has officially restarted patient dosing in its Phase III MARIO trial for Brexafemme (ibrexafungerp) after the FDA lifted a nearly two-year clinical hold. The hold, initiated over concerns of beta-lactam contamination at the original manufacturing facility, was removed once new drug batches were produced at a separate location. With trial sites now reactivated, patient enrollment has resumed, reaching about 25% of its 220-participant goal. A pharmacist technician sorting pills in a drug pharmacy. The MARIO trial explores Brexafemme's use as an oral follow-up treatment to IV echinocandins for invasive candidiasis, a life-threatening fungal infection. SCYNEXIS, Inc. (NASDAQ:SCYX) received a $10 million milestone payment from GSK after the first new patient was dosed, though disagreements over further payments and trial duties have sparked tension between the two partners. Previously recalled in 2023 due to contamination risks, Brexafemme had FDA approval for treating VVC. While its commercial progress has faced setbacks, projected global revenue could reach $139 million by 2031 if development succeeds. While we acknowledge the potential of SCYX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SCYX and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Scynexis resumes dosing in Phase III MARIO study after lengthy delay
Scynexis has resumed dosing of its vaginal yeast infection drug Brexafemme (ibrexafungerp) in a Phase III trial after a 19-month clinical hold by the US Food and Drug Administration (FDA). The resumption of dosing in the MARIO study (NCT05178862) comes after the FDA lifted the clinical hold last month, originally in place due to concerns about cross-contamination. Scynexis said the investigational sites were reactivated a few days ago, as per a 28 May press release. The issue was highlighted after a review from GSK, which signed a licensing deal for the drug with Scynexis in 2023. The British big pharma noted that the manufacturing site for Brexafemme also produced a non-antibiotic beta-lactam substance. This drug, which can cause allergic reactions in some patients, has been the subject of an FDA draft guidance that details the separation of manufacturing processes for these compounds. In September 2023, Scynexis issued a voluntary recall of Brexafemme, an FDA-approved treatment for vulvovaginal candidiasis (VVC), due to the potential for cross-contamination. Scynexis said the study has resumed following the manufacture of new clinical supplies at another site. The Phase III MARIO study is investigating oral Brexafemme as a potential step-down antifungal therapy following intravenous (IV) echinocandin for invasive candidiasis, a potentially life-threatening infection. The trial has enrolled around 25% of its 220-patient target. 'We are pleased to announce the dosing of the first new patient in the Phase III MARIO study following the lifting of the clinical hold by the FDA in April,' said Scynexis CEO David Angulo. 'The rapid resumption of patient enrolment, just a few days after the investigational sites were reactivated in the study, reflects the eagerness of the scientific community to have new treatment options for this life-threatening infection.' MARIO being back on track comes amid a saga between Scynexis and GSK, with the companies pointing fingers at each other with regard to trial duties. During its Q1 earnings report, Scynexis said that GSK had tried to terminate the study, with Angulo affirming plans to move forward with Brexafemme in this new indication. There used to be substantial cash on the line. The partnership in 2023 included not just a $90m upfront payment, but up to $503m in milestone payments. However, after the commercial delays, millstone payments were cut in a revised deal in December 2023. Approval-based milestones were slashed from $70m to $49m, whilst commercial counterparts were halved from $115m to a potential $57.5m. Milestone payments based on sales were also downwardly revised. By dosing the first new patient, Scynexis believes it has now triggered a $10m payment, with another $20m to arrive by the six-month anniversary of dosing. 'As previously disclosed, there is a disagreement between Scynexis and GSK regarding the resumption of the MARIO Study and GSK's responsibility for paying these milestones. Scynexis is working to resolve the disagreement,' Scynexis said in a statement. GSK did not immediately respond to Clinical Trials Arena's request for comment. Scynexis reported $3.7m in revenue for 2024, which primarily consisted of the licence agreement with GSK. Brexafemme generated sales of $5m in 2022 before the recall. GlobalData's Pharma Intelligence Center forecasts global sales of $139m by 2031, a valuation that hinges on the outcome of the MARIO study and a subsequent label expansion. GlobalData is the parent company of Clinical Trials Arena. "Scynexis resumes dosing in Phase III MARIO study after lengthy delay" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
